Alerta

一种具有线粒体/STAT3蛋白双位点靶向的光疗纳米药物及其制备方法与应用

Resumen de: CN121570586A

本发明公开了一种具有线粒体/STAT3蛋白双位点靶向的光疗纳米药物，化合物CR和阿托伐醌在二硬脂酰基磷脂酰乙醇胺‑聚乙二醇作用下自助装而成的ATO/CR纳米颗粒；化合物CR的结构如式Ⅰ所示。本发明公开了所述的具有线粒体/STAT3蛋白双位点靶向的光疗纳米药物在制备治疗肿瘤药物中的应用。本发明光疗纳米药物既可以通过ATO靶向肿瘤细胞内的线粒体和STAT3蛋白，还可以通过纳米颗粒的高渗透长滞留效应被动靶向肿瘤部位，使得纳米治疗剂更多的富集在肿瘤周围，提高疗效。本发明光疗纳米药物具有良好的光热性能，能有效增强胃癌PTT效应，通过促进细胞凋亡、抑制血管生成、阻碍细胞周期发挥肿瘤协同治疗能力。

一种降血脂的姜黄素/胡椒碱复合颗粒及其制备方法和应用

Resumen de: CN121570434A

本发明提供了一种降血脂的姜黄素/胡椒碱复合颗粒及其制备方法和应用，属于营养活性成分递送体系技术领域。本发明以姜黄素/玉米醇溶蛋白为核，采用反溶剂沉淀法结合逐层组装技术，加入卡拉胶调控玉米醇溶蛋白颗粒的表面性质，并使用Ca2+对卡拉胶层进行交联，同时吸附和封装胡椒碱，最后以羧甲基壳聚糖为最外层，构建得到“核‑壳‑壳”层层结构的姜黄素‑玉米醇溶蛋白‑卡拉胶‑胡椒碱‑羧甲基壳聚糖复合颗粒。相较于游离姜黄素和胡椒碱，本发明制备的复合颗粒可提高姜黄素和胡椒碱的理化稳定性，增强二者的生物活性和效能性能，有更强的预防高脂血症功效，在降血脂功能产品开发方面拥有良好的应用前景。

一种仿生黑磷纳米材料及其制备和应用

Resumen de: CN121570436A

本发明公开了一种仿生黑磷纳米材料及其制备和应用，包括以下步骤：S1、黑磷纳米片的制备；S2、羧基化黑磷纳米片的制备；S3、复合黑磷纳米材料的制备；S4、仿生黑磷纳米材料的制备。该仿生黑磷纳米材料的结构核心由黑磷纳米片构成，经双端羧基聚乙二醇修饰后，可通过其末端羧基与氨基修饰的Anti miR 33核酸抑制剂进行共价连接，以达到保护核酸结构、提升递送效率的目的，随后采用来源于M2c表型巨噬细胞的细胞膜对材料进行包被，从而赋予该材料炎症区域的主动靶向能力。

이온화 가능한 지질 및 그 응용

Resumen de: AU2024307443A1

The present invention provides an ionizable lipid and a drug delivery system comprising the ionizable lipid. Specifically, the present invention provides an ionizable lipid having a structure of formula (I), or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof. Lipid nanoparticles constructed by using the ionizable lipid can realize safe and efficient delivery of nucleic acid drugs, small molecule drugs, peptide drugs and protein drugs.

폴리시알산-중합체 컨쥬게이트 및 나노입자

Resumen de: MX2025012226A

Disclosed herein is a polysialic acid (PSA)-polymer conjugate compound represented by the structural formula (I): or a pharmaceutically acceptable salt thereof, wherein P is a poly(lactide-co-glycolide)-poly(ethylene glycol) copolymer (PLGA-PEG) and p is an integer from 4 to 200, nanoparticles comprising same, and methods of treating ophthalmic diseases using same.

Nanoparticle complex for photothermal immunotherapy and pharmaceutical composition for the prevention or treatment of cancer containing the same

Resumen de: KR20260026625A

일 양상에 따른 광열 면역 치료를 위한 나노 입자 복합체 및 이를 포함하는 암의 예방 또는 치료용 약학적 조성물은 근적외선 레이저에 의해 암세포를 파괴하고, 면역 세포를 활성을 유도하여 암의 전이와 재발을 억제하는 효과가 있다.

ナノ粒子としてのｔＲＮＡ送達用組成物およびその使用方法

Resumen de: EP4393549A2

In some aspects, the present disclosure provides a nanoparticle composition comprising tRNA and an aminolipid delivery compound. The aminolipid delivery compound may be a dendrimer, dendron, or dendritic lipid, a polymer such as a polyamide or polyester, or a lipid with one or more hydrophobic components. In some embodiments, these compositions may be administered to a patient to treat a genetic disease or disorder such as cystic fibrosis, Duchene muscular dystrophy, or cancer.

ファイトケミカルを含むアルブミンナノ複合体およびそれを含む筋肉疾患改善用組成物

Resumen de: US2025367305A1

The present disclosure relates to an albumin nanocomposite comprising a phytochemical and a composition for muscle disease comprising the same, and more specifically, to an albumin nanocomposite comprising a phytochemical that exhibits an effect of inhibiting muscle loss caused by oxidative stress or inflammatory response and promoting the differentiation of myoblasts into muscle cells. The albumin nanocomposite comprising the phytochemical effectively delivers the phytochemical by targeting immune cells that induce reactive oxygen species and inflammatory responses. Accordingly, by regulating muscle-loss signaling pathways induced by reactive oxygen species and inflammatory responses, the nanocomposite inhibits muscle cell atrophy and promotes differentiation. Therefore, a composition comprising the albumin nanocomposite comprising the phytochemical according to the present disclosure can be provided as a composition for improving, preventing, or treating muscle diseases.

磁気共鳴イメージングにおいて酸化鉄ナノ粒子を使用して節病変を評価する方法

Resumen de: CN120813831A

The present invention relates to a method for assessing lymph node disease by magnetic resonance imaging using a contrast agent. The contrast agent includes biologically functional magnetic nanoparticles coated with a polymer outside an iron core and conjugated with an antibody having specificity to a tumor type to be evaluated. An image generated from such magnetic resonance imaging using a contrast agent shows a heterogeneous low intensity or a heterogeneous configuration in the region where binding by the antibody is present.

ＴＧＦ－β－２およびイリノテカン剤によるがん療法

Resumen de: US2025382619A1

This invention describes methods for treating or ameliorating the symptoms of cancer in a subject with agents, compositions and regimens designed to promote anti-tumor effects and avoid drug resistance effects. Combinations of active agents can be used including agents for inhibiting or suppressing expression of TGF-β2 in combination with an irinotecan-containing agent, regimen or formulation, for example, a FOLFIRINOX agent, a NALIRIFOX agent, an IRIFOX agent, or an IRINOX agent. Biomarkers can be used to select subjects who benefit from such therapeutics.

一种二甲双胍增强PARP抑制剂及其制备方法和应用

Resumen de: CN121570467A

本发明公开了一种二甲双胍增强PARP抑制剂及其制备方法和应用，属于生物医药技术领域，具体涉及一种二甲双胍增强PARP抑制剂；该PARP抑制剂包括二甲双胍和奥拉帕尼；奥拉帕尼和二甲双胍的摩尔比为1:200‑600。本发明通过二甲双胍重塑不同BRCA1突变亚型三阴性乳腺癌细胞的能量代谢状态，显著增强奥拉帕尼在耐药环境下对该类癌细胞的抑制作用，并有效促进细胞凋亡、抑制细胞迁移，从而实现对PARP抑制剂疗效的协同提升。

一种负载抗病毒药物的功能化纳米颗粒，以及一种基于原位催化产氧的胶原基水凝胶滴眼液及其制备方法和用途

Resumen de: CN121570613A

一种负载抗病毒药物的功能化纳米颗粒，以及一种基于原位催化产氧的胶原基水凝胶滴眼液及其制备方法和用途。本发明提供了雪花状二氧化锰纳米颗粒SM在制备作为胶原基水凝胶眼用制剂载体或辅料中的应用。本发明还提供了一种负载抗病毒药物的功能化纳米颗粒，它是以雪花状二氧化锰纳米颗粒SM为载体，负载抗病毒药物。本发明还提供了一种基于原位催化产氧的胶原基水凝胶滴眼液。本发明针对病毒性角膜炎的、首次融合智能药物递送、原位氧合治疗与免疫微环境调节的原创性平台技术，本申请克服了目前报道的方法无法治疗病毒感染、依赖外部设备、且不能调控宿主病理微环境的固有缺陷，提供了一种更智能、集成、安全且患者友好的HSK治疗新策略，具有显著的进步性和突出的实质性特点。

一种多功能PEG化脂质衍生物及脂质纳米颗粒共递送系统

Resumen de: CN121574374A

本发明属于药物递送系统技术领域，具体涉及一种多功能PEG化脂质衍生物及脂质纳米颗粒共递送系统。所述多功能PEG化脂质衍生物为DSPE‑PEG2000‑R8‑FRRG‑IMI。所述脂质纳米颗粒共递送系统以脂质纳米颗粒为载体，siRNA和顺铂前药包载于所述脂质纳米颗粒内部。其中，所述脂质纳米颗粒由可电离阳离子脂质、DSPC、胆固醇和PEG化脂质衍生物组成，所述PEG化脂质衍生物为DSPE‑PEG2000‑R8‑FRRG‑IMI。所述脂质纳米颗粒共递送系统不仅能够实现顺铂前药与siRNA共载，在杀伤肿瘤的同时克服顺铂耐药，而且具有主动靶向性、刺激响应性以及高效胞内逃逸功能，对于肺腺癌或乳腺癌等具有显著的治疗效果。

包含工程改造的苯丙氨酸氨裂解酶(PAL)的功能化组合物

Resumen de: AU2024289116A1

The present invention relates to a composition comprising a solid carrier, an engineered phenylalanine ammonia lyase or a fragment thereof immobilized on the surface of the solid carrier, a protective layer to protect the engineered phenylalanine ammonia lyase or a fragment thereof by embedding the engineered phenylalanine ammonia lyase or a fragment thereof, and a functional constituent immobilized on the surface of the protective layer, wherein the functional constituent immobilized on the surface of the protective layer is a polymer comprising repeat units wherein each repeat unit comprises at least one amino group and/or at least one thiol group. The present invention also relates to methods of producing said composition and uses thereof.

一种用于治疗铜绿假单胞菌角膜炎的纳米颗粒及其制备方法

Resumen de: CN121570587A

本发明公开了一种用于治疗铜绿假单胞菌角膜炎的纳米颗粒及其制备方法和应用，该纳米颗粒能够有效解决多重耐药铜绿假单胞菌带来的治疗难题。该纳米颗粒通过消耗细菌内的谷胱甘肽并诱导硫超载，破坏细菌的氧化还原平衡和结构代谢，从而逆转其耐药性。同时，该纳米颗粒表面具有径向刺突，能够高效地跨越细菌的外排泵和生物膜屏障，提高药物在细菌细胞内的递送效率。此外，该纳米颗粒结合光热治疗，与抗生素载荷协同作用，进一步增强了抗菌效果。实验表明，该纳米颗粒显著降低了多种抗生素的最小抑菌浓度，恢复了其抗菌效力，并在小鼠角膜炎模型中成功恢复了角膜透明度和健康。本发明为治疗细菌性角膜炎提供了一种创新的、高效的解决方案。

DNA ORIGAMI VACCINES

Resumen de: US20260053906A1

Disclosed herein is a vaccine device that involves a DNA origami nanostructure formed from a plurality of scaffold strands and a plurality of staple strands assembled into a rod shape, wherein a peptide antigen is attached to the DNA of the nanostructure by electrostatic interaction. Also disclosed herein is a method for vaccinating a subject that involves administering to the subject a therapeutically effective amount of a vaccine device disclosed herein.

RESORBABLE SHEET MATERIAL COMPRISING POROUS COLLAGEN SPONGE AND NANOPARTICLES OR MICROPARTICLES WHICH RELEASE ACTIVE INGREDIENTS IN A CONTROLLED MANNER, USE THEREOF, AND METHOD FOR THE PRODUCTION THEREOF

Resumen de: WO2026041516A1

The invention relates to a profiled sheet material which has a resorbable porous collagen sponge in which resorbable nanoparticles or microparticles or combinations thereof are dispersed, wherein the nanoparticles or microparticles have at least two different release profiles for the controlled and/or delayed release of pharmaceutical active ingredients. The invention further relates to a method for producing the sheet material and to the use thereof in a method for treating wounds or in a method for local pharmacotherapy.

COMPOSITIONS AND METHODS OF USE THEREOF FOR PREVENTION OF MASTITIS

Resumen de: US20260053746A1

Disclosed herein are compositions and methods of use thereof for the prevention of mastitis in dairy cattle. The compositions and methods can have immunostimulant effectiveness against mastitis-causing bacteria. In particular embodiments, the methods include preventing mastitis infection by intramammary infusion of a disclosed composition at dry-off.

METHODS AND COMPOSITIONS FOR SUSTAINED RELEASE MICROPARTICLES FOR OCULAR DRUG DELIVERY

Resumen de: US20260053737A1

In one aspect, the disclosure relates to relates to compositions, devices, and processes for drug delivery to an eye. The disclosed drug delivery compositions comprise a particle having a core component comprising a first polymer and a therapeutic agent, and a shell layer surrounding the core component comprising a second polymer. In a further aspect, the present disclosure relates to methods of treating an ophthalmological disease or disorder. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.

PARENTERAL COMPOSITIONS OF ZILEUTON AND METHODS OF USE

Resumen de: US20260053774A1

Provided herein are compositions containing zileuton formulated for parenteral administration and/or extended use. Methods of treatment are directed to subjects who would benefit from extended use of zileuton to provide renal protective effects.

Sustained Nitric Oxide Releasing Drug Delivery Systems

Resumen de: US20260053768A1

Disclosed herein are drug delivery vehicle compositions, comprising lipid nanoparticle-forming molecules, a nitric oxide donor (NO-donor) molecule, and a hydrogel. Also disclosed are methods of making the same by mixing the lipid nanoparticle-forming molecules and the NO-donor in a hydrophobic solvent to form a first mixture; and adding a mixture of hydrogel and water, and optionally a buffer solution, to the first mixture to form the drug delivery vehicle composition. In addition, disclosed herein are methods of treating a patient suffering from a disease that can be treated with nitric oxide, the method comprising identifying a patient in need thereof, and administering to the patient a drug delivery vehicle disclosed herein.

NANOCOMPOSITION COMPRISING ANTIBODY-DRUG CONJUGATE AND USE THEREOF

Resumen de: US20260053943A1

This disclosure is directed to a pharmaceutical composition for treating or preventing a disease. The pharmaceutical composition can comprise a targeting bioactive agent (TBA); a payload bioactive agent (PBA) covalently linked to the targeting bioactive agent (TBA) directly or indirectly; and, optionally, a polymer forming nanoaggregates. The pharmaceutical composition can comprise Ag+ tumor cytotoxicity to tumor cells having a tumor antigen (Ag+ tumor cells) and Ag− tumor cytotoxicity to tumor cells free from a tumor antigen (Ag− tumor cells). The pharmaceutical composition can be an antibody-drug conjugate (ADC) for treating cancers having tumor antigen positive (Ag+) tumor cells, tumor antigen negative (Ag−) tumor cells, or heterogenous cancers having both tumor antigen positive (Ag+) tumor cells and tumor antigen negative (Ag−) tumor cells.

OXIDIZED CARBON PEG-OAC NANOZYMES FOR MITOCHONDRIAL DISORDERS

Resumen de: US20260053946A1

The present invention is directed to a composition and a method for treating a mammal exhibiting an inherited mitochondrial disease. That method comprises administering a pharmaceutical composition containing a mitochondria-treating effective amount of PEG-OAC nanozymes, DEF-OAC-PEG nanozymes or both nanozymes dissolved or dispersed in a physiologically tolerable diluent. In that composition, PEG is an acronym for a reacted alpha-amino-omega-methoxy-poly(ethylene glycol) substituent, OAC is an acronym for oxidized activated charcoal particle, and DEF is an acronym for a reacted deferoxamine substituent. Both of the PEG and the DEF substituents are each covalently bonded to the OAC particle by the primary amino group on each.

Benzaldehyde acetal acid-degradable amphiphilic lipid and self-assembling peptides

Resumen de: US20260053954A1

Compounds comprising a benzaldehyde acetal acid-degradable amphiphilic lipid and self-assembling peptides are incorporated in lipid nanoparticle (LNP) and used to transfect cells.

COMPOSITIONS AND METHODS FOR IMPROVING COGNITIVE FUNCTION

Nº publicación: US20260053831A1 26/02/2026

Solicitante:

DIAMOND THERAPEUTICS INC [CA]
Diamond Therapeutics Inc

Resumen de: US20260053831A1

Disclosed herein are methods for managing disorders or conditions, or treating symptoms of disorders or conditions, comprising administering 5HT receptor agonists. The disorders may involve cognitive function and the methods of improving may comprise administering low doses of 5HT receptor agonists to subjects in need thereof. Improvement of the symptoms of a disorder involving cognitive function can be achieved where the disorders comprise mood, cognitive, anxiety, and depression disorders. Also disclosed herein are pharmaceutical compositions, formulations, and dosage forms of 5HT receptor agonists.